Anne Wood Beaven MD

Cutaneous Lymphoma, Hematologic Oncology

Director of Lymphoma Program, Associate Professor of Medicine

2100 Erwin RdDurham, NC 27705
Phone+1 919-684-8111
Fax+1 919-966-6735

Dr. Beaven is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Beaven's full profile Already have an account?

Summary

Dr. Beaven cares for patients with all types of lymphoma, with a particular interest in T cell lymphoma. Along with Dr. Edith Bowers in dermatology, she runs a multidisciplinary Cutaneous lymphoma clinic.(https://unclineberger.org/patientcare/programs/lymphoma/cutaneous)

Her main area of research is the development of CarT clinical trials. The CD30 CarT trials are for patients with relapsed/refractory CD30+ lymphomas, which include Hodgkin lymphoma as well as some systemic T cell lymphomas such as anaplastic large cell lymphoma, and some cutaneous T cell lymphomas. In the near future they plan to open trials in both indolent and aggressive B cell lymphomas as well.

https://unclineberger.org/people/profiles/anne-beaven

Education & Training

University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2004 - 2007
University of North Carolina HospitalsResidency, Internal Medicine, 2000 - 2004
University of North Carolina at Chapel Hill School of MedicineClass of 2000

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NC State Medical License 2003 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017

Clinical Trials

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL Start of enrollment: 2016 Aug 26
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma Start of enrollment: 2019 Sep 17
RECRUITING
PHASE2
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma Start of enrollment: 2023 Oct 20
RECRUITING
PHASE3
Roles: Principal Investigator, Contact

Publications & Presentations

PubMed

Utility of a modified geriatric assessment to identify impairments in adults of all ages with lymphoma: A prospective observational cohort study.
Christopher E Jensen, Hrishika Muthukrishnan, Kirsten A Nyrop, Natalie S Grover, Christopher E Dittus
Journal of Geriatric Oncology. 2026-08-04
Racial differences in mycosis fungoides and Sézary syndrome: A multicenter cohort study.
Pamela B Allen, Subir Goyal, Swaminathan Iyer, Sai Talluru, Auris Huen
Journal of the American Academy of Dermatology. 2026-02-01
Primary Bone Lymphoma of the Jaw Masquerading as Infection and Delaying Treatment.
Emily Hamburger, Anne W Beaven
Hematology Reports. 2026-01-22

Abstracts/Posters

High Risk Cytogenetic and Immunohistochemistry Findings in Monomorphic Post-Transplant Lymphoproliferative Disorder Following Solid Organ Transplant _ a Single Center ...
Anne Beaven, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
Anne Beaven, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

When Transplant Has Failed or Is Not an Option: What Do I Do for My Patient with Hodgkin Lymphoma?
ASCO Annual Meeting 2019 - Chicago, IL - 5/3/2019

Press Mentions

'Nursing Is Dangerous': What We Heard This WeekJune 19th, 2020
Stand up to Cancer Dream Team Tackles T-cell Lymphoma, Focused on CAR-Based StrategiesJanuary 28th, 2019
NCCN Awards Grants to Three Researchers to Investigate Volasertib in Hematologic MalignanciesFebruary 10th, 2016